
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic Inc. is demonstrating encouraging progress in its clinical development, particularly with its lead candidate, vidofludimus calcium, for the treatment of relapsing multiple sclerosis (RMS), supported by positive results from the Phase 2 CALLIPER and EMPhASIS trials that indicate reductions in disability worsening and improved safety profiles. The additional data underscores the drug's potential neuroprotective effects and anti-viral activity against chronic EBV infection, which is believed to influence disease progression in MS patients. As the company advances into pivotal trials for RMS, these promising findings contribute to a favorable outlook on Immunic's stock performance, reflecting the strength of its pipeline in addressing chronic inflammatory and autoimmune diseases.
Bears say
Immunic Inc. is experiencing significant financial challenges that contribute to a negative outlook on its stock. The company has recently faced a decrease in the effectiveness of its leading treatment candidates, as evidenced by the drop in gadolinium-enhancing lesions in patients receiving vidofludimuscalcium, which suggests potential issues in achieving commercial success. Additionally, the company continues to incur substantial operating losses, with quarterly expenses totaling $26 million juxtaposed against a backdrop of limited capital resources and a recent downward revision of price targets, raising concerns about its ability to fund ongoing operations and development.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares